The Online Investor
OLI Premium
Retiree Portfolio
Stock Option Ideas
Preferred Stock List
ChartZero.com
ChartZero

Slideshow Secondary Stock Offerings

By The Online Investor Staff, updated Sun., Apr. 26, 9:45 PM

Slide #5. Lipocine Secondary Offering

Company: Lipocine (NASDAQ:LPCN)
Date announced: 4/23/2015
Shares Offered: 4,650,000
Date of Pricing: 4/24/2015
Price Per Share: $6.50
Secondary Offering Details: Lipocine Inc. (Nasdaq:LPCN), a specialty pharmaceutical company, today announced that it has commenced an underwritten public offering of its common stock. In addition, Lipocine expects to grant the underwriters a 30-day option to purchase up to an additional 15 percent of the shares of common stock offered in the public offering solely to cover over-allotments, if any. The offering is subject to market conditions and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. - updated 4/24 - Lipocine Inc. (Nasdaq:LPCN), a specialty pharmaceutical company, today announced that it has priced an underwritten public offering of 4,650,000 shares of its common stock at $6.50 per share for gross proceeds of $30.2 million. Lipocine has also granted the underwriters a 30-day option to purchase up to an additional 697,500 shares of common stock to cover over-allotments, if any. The offering is expected to close on or about April 29, 2015, subject to satisfaction of customary closing conditions.

Lipocine is a pharmaceutical company engaged in research and development for the delivery of drugs using its delivery technology. Co.'s principal operation is to provide oral delivery solutions for existing drugs. Co. develops its own drug candidates or it develops drug candidates on behalf of or in collaboration with corporate partners. Co.'s primary product candidate LPCN 1021 is an oral testosterone replacement therapy, , designed for convenient twice-a-day dosing. Additionally, Co. has two earlier stage product candidates in its pipeline, an oral testosterone therapy, LPCN 1111, and an oral product candidate for the prevention of preterm birth, LPCN 1107.
Open the LPCN Page at The Online Investor »

Company Name:  Lipocine Inc (New)
Sector:  Drugs & Pharmaceuticals
Number of ETFs Holding LPCN:  1
Total Market Value Held by ETFs:  $192197
Total Market Capitalization:  $93.00M
% of Market Cap. Held by ETFs:  0.21%
 

Open the LPCN Page at The Online Investor (in a new window) »

April 26, 2015    9:45 PM Eastern
Quotes delayed 20 minutes



Strong Buy (4.00 out of 4)
88th percentile
(ranked higher than approx. 88% of all stocks covered)
Based on Zacks ABR data;
powered by Xignite

Secondary Stock Offerings | www.TheOnlineInvestor.com | Copyright © 1998 - 2015, All Rights Reserved

Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes, powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.